Skip to main content
Utility Menu
Patients
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Patients
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Charcot-Marie-Tooth Disease
Our Science
Gene Therapy Engine
RNA Platform
Gene Editing
Manufacturing
Strategic Partnerships
Investigator-Initiated Studies
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM)
Our Disease Areas
Our Science
Limb-girdle muscular dystrophy (LGMD)
Join Us
RNA Platform
Gene Editing
Clinical Trials
Community Letter: SRP-9001 Advisory Committee Date is Announced
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
Pagination
First page
« First
Previous page
‹ Previous
…
Page
37
Page
38
Page
39
Page
40
Page
41
Page
42
Current page
43
Page
44
Page
45
Next page
Next ›
Last page
Last »
